CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020.

Read more:
Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting

WATERTOWN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Evercore ISI 3rd Annual HealthCONx on Thursday, December 3, 2020 at 8:25 a.m. ET.

Visit link:
C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx

Simple, single-dose nasal spray offers greater ease and comfort of administration; positioning AdCOVID as a differentiated vaccine candidate for adults and children

Excerpt from:
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence...

LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM – 11:15 AM EST.

Follow this link:
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference

TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

Continue reading here:
Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference

GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference.

Go here to see the original:
Novavax to Participate in Upcoming Conferences

AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.

More:
Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has approved DANYELZA (naxitamab-gqgk) 40mg/10ml. DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval regulation based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA is a humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. DANYELZA is administered to patients three times in a week in an outpatient setting and the treatment is repeated every four weeks. The product has received Priority Review, Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease designations from the FDA.

See more here:
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

DXS INTERNATIONAL PLC

View post:
Half-year report

Please read the full announcement in PDF

View post:
Change of management

MISSISSAUGA, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2020. Key highlights include:

See original here:
BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020

On “Grindeks” results in the first nine months of 2020

View original post here:
On “Grindeks” results in the first nine months of 2020

Company announcement no. 48 - 20 26 November 2020

Continue reading here:
Notification of Managers’ transactions

PRESS RELEASE

Follow this link:
Saniona AB’s Nomination Committee for the Annual General Meeting 2021

WINNIPEG, Manitoba, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced their third quarter 2020 financial results.

Here is the original post:
Kane Biotech Announces Third Quarter 2020 Financial Results

STRATHROY, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce its financial results for the three and nine months ended September 30, 2020. The financial statements and management’s discussion and analysis for such period are available on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com and on Eve & Co's website at www.evecannabis.ca.

Read the rest here:
Eve & Co Announces Financial Results for the Three and Nine Months Ended September 30, 2020

TORONTO, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Braingrid Limited (CSE: BGRD) (“Braingrid” or the “Company”) is pleased to announce that Gregory Pepin has been appointed to the Company’s Board of Directors.

See more here:
Braingrid Limited Announces Changes to Board of Directors

VANCOUVER, British Columbia, Nov. 26, 2020 (GLOBE NEWSWIRE) -- EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”) is providing this bi-weekly default status report in accordance with National Policy 12-203 Management Cease Trade Orders (“NP 12-203”). On October 23, 2020, the Company announced that, for reasons set out in its news release of October 23, 2020, the filing of its annual audited financial statements for the year ended June 30, 2020, the accompanying management’s discussion and analysis and the related CEO and CFO certifications (collectively, the “Annual Filings”) would not be filed by the prescribed deadline of October 28, 2020.

See the rest here:
EXMceuticals Provides Bi-Weekly Default Status Report

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 at 2:00 p.m. ET.

See the rest here:
Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020

BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced that management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 12:35 p.m. ET.

See the original post:
Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference